Adaptive and Innate Immune Responsiveness to Borrelia burgdorferi sensu lato in Exposed Asymptomatic Children and Children with Previous Clinical Lyme Borreliosis by Skogman, Barbro H. et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 294587, 10 pages
doi:10.1155/2012/294587
Research Article
Adaptive and InnateImmuneResponsivenesstoBorrelia
burgdorferisensulato inExposedAsymptomatic Childrenand
Childrenwith Previous Clinical LymeBorreliosis
BarbroH.Skogman,1,2 SandraHellberg,3 ChristinaEkerfelt,3 Maria C. Jenmalm,3
PiaForsberg,4 Johnny Ludvigsson,5 SvenBergstr¨ om,6 and Jan Ernerudh3
1Department of Pediatrics, Falun General Hospital, 791 82 Falun, Sweden
2Centre for Clinical Research in Dalarna, Nissers v¨ ag 3, 791 82 Falun, Sweden
3Division of Clinical Immunology, Department of Clinical and Experimental Medicine, Link¨ oping University,
581 85 Link¨ oping, Sweden
4Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Link¨ oping University, 581 85 Link¨ oping, Sweden
5Division of Pediatrics, Department of Clinical and Experimental Medicine, Link¨ oping University, 581 85 Link¨ oping, Sweden
6Department of Molecular Biology, Ume˚ a University, 901 87 Ume˚ a, Sweden
Correspondence should be addressed to Barbro H. Skogman, barbro.hedinskogman@ltdalarna.se
Received 7 June 2011; Revised 25 August 2011; Accepted 29 August 2011
Academic Editor: Joanna Zajkowska
Copyright © 2012 Barbro H. Skogman et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Why some individuals develop clinical manifestations in Lyme borreliosis (LB) while others remain asymptomatic is largely
unknown. Therefore, we wanted to investigate adaptive and innate immune responsiveness to Borrelia burgdorferi sensu lato in
exposed Borrelia-antibody-positive asymptomatic children (n = 20), children with previous clinical LB (n = 24), and controls
(n = 20).BloodsampleswereanalyzedforBorrelia-speciﬁcinterferon(IFN)-γ,interleukin(IL)-4,andIL-17secretionbyELISPOT
and Borrelia-induced IL-1β, IL-6, IL-10, IL-12(p70), and tumor necrosis factor (TNF) secretion by Luminex. We found no
signiﬁcant diﬀerences in cytokine secretion between groups, but a tendency towards an increased spontaneous secretion of IL-
6 was found among children with previous clinical LB. In conclusion, the adaptive or innate immune responsiveness to Borrelia
burgdorferi sensu lato was similar in Borrelia-exposed asymptomatic children and children with previous clinical LB. Thus, the
immunological mechanisms of importance for eradicating the spirochete eﬀectively without developing clinical manifestations of
LB remain unknown.
1.Introduction
Lyme Borreliosis (LB), caused by the spirochete Borrelia
(B.) burgdorferi, is the most common tick-borne infection
in both Europe and the USA [1, 2]. The infection may lead
to a variety of symptoms by aﬀecting diﬀerent organs such
as the skin, joints, heart muscle, or nervous system. The
most common manifestation of LB is the migrating red
skin lesion called erythema migrans (EM). LB in children
follows a slightly diﬀerent clinical course than in adults, and
duration of symptoms is often shorter [3]. Children seem to
have a better prognosis than adults and more seldom report
persisting symptoms [4–6].
The cells of the innate immune system, constituting the
ﬁrstlineofdefense,recognizepathogen-associatedmolecular
patterns (PAMPs) through pattern-recognition receptors
(PRRs) like Toll-like receptors (TLRs) [7]. The spirochete B.
burgdorferi contains a high proportion of lipoproteins that
are mainly recognized by TLR2 [8]. Recognition of B.
burgdorferi leads to the release of inﬂammatory mediators
like interleukin (IL)-1β, IL-6, IL-10, and IL-12, and tumor
necrosis factor (TNF) from monocytes, macrophages, neu-
trophils, and DCs [9–12]. These cytokines are important for
recruitment of other components of the innate host immune
response but also for signaling with the adaptive immune2 Clinical and Developmental Immunology
system [12]. The adaptive immune system consists of T and
B lymphocytes and comprises the second line of defense
to eliminate the spirochete. Activated T helper (Th) cells
diﬀerentiate into Th1, Th2, Th17 or T-regulatory cells [13].
Th1 cells are important for immunity against intracellular
pathogens, whereas Th2 cells are involved in immune
responses against extracellular parasites [14]. Typical Th1
and Th2 eﬀector cells are macrophages and mast cells,
respectively. Th1 and Th2 are deﬁned by their signature
cytokines IFN-γ and IL-4, which act antagonistically to
counterbalance each other. Th17 cells, producing IL-17, are
involved in the defense against fungi and some extracellular
bacteria [15]. The immune response to B. burgdorferi
involves both humoral and cell-mediated immune responses
where both T-cell-independent and -dependent B cell re-
sponses are important during the adaptive immune re-
sponse for killing the spirochetes [12].
Children and adults diﬀer in the type of immune re-
sponse they evoke when encountering B. burgdorferi.In
adults, the immune response in LB is characterized by a
strong Th1 responses with high numbers of Borrelia-speciﬁc
IFN-γ-secreting cells and low levels of IL-4 [16, 17], whereas
children seem to have a more balanced immune response
with elevated secretion of both IFN-γ and IL-4 [18]. It has
been hypothesized that the type of immune response evoked
inthepresenceoftheBorreliaspirochetemayhavesigniﬁcant
eﬀect on the clinical course and the outcome of the infection
[19]. Persistent symptoms after LB were associated with a
strong IFN-γ response but lacked the subsequent upregu-
lation of IL-4 [19]. Thus, it appears that a later prominent
Th2 immune response is necessary to downregulate the
initial strong IFN-γ response in order to eﬀectively terminate
the infection and hinder unsatisfactory tissue damage.
This could be one possible explanation why children
usually experience a more benign course of the disease as
they show both strong Th1 and Th2 immune responses
[18].
The fact that some individuals may be exposed to B.
burgdorferis.l.withoutdevelopingclinicalsymptomsisinter-
esting fromanimmunological standpoint and couldindicate
am o r ee ﬀective immune response to the spirochete in
these individuals. In adults, the term asymptomatic Borrelia
infection is used for individuals who have been exposed
to B. burgdorferi s.l. (i.e., with Borrelia IgG antibodies in
serum) without known previous clinical LB [20]. These
asymptomatic individuals have been found to have a higher
secretion of the proinﬂammatory cytokines IL-12 and TNF
than patients with clinical LB, suggesting an enhanced innate
activity [21]. As for the adaptive immune responses, no dif-
ferences have been found in Borrelia-speciﬁc IFN-γ and IL-
4 secretion when comparing Borrelia exposed asymptomatic
adults to patients with clinical LB [20]. To our knowl-
edge, the innate and adaptive immune responses have not
previously been studied in Borrelia exposed asymptomatic
children.
T h ea i mo ft h i ss t u d yw a st oi n v e s t i g a t ea d a p t i v ea n d
innate immune responsiveness to Borrelia exposed asymp-
tomatic children as compared to children with previ-
ous clinical LB to elucidate immunological mechanisms
that might contribute to an eﬀective eradication of the
pathogen.
2.MaterialsandMethods
Children recruited to participate in this study were initially
included in a larger prospective study, the ABIS (All Babies
In Southeast Sweden) study, with the primary purpose of
ﬁnding risk factors for immune-mediated diseases, mainly
Type 1 diabetes (n = 17 055). These children were followed
until at 5 years of age at primary health care centers. All
participating families completed a validated questionnaire,
and venous or capillary blood samples were collected
in conjunction with the 5-year followup. Two thousand
children were randomly selected and screened for Borrelia
IgG antibodies in serum [22]. Information concerning
gender, geographic location, known tick bites, previous LB,
and antibiotic treatment for LB was collected from the
questionnaire.
Of these 2000 children, a total number of 64 children,
geographically spread, were chosen to represent three major
groups: Borrelia exposed asymptomatic children (n = 20),
children with previous clinical LB (n = 24), and controls
(n = 20) (Table 1). Borrelia exposed asymptomatic children
were characterized by having Borrelia IgG antibodies in
serum, but they reported no previous symptoms or treat-
ment for LB in the questionnaire. Children with previous
clinical LB reported previous treatment for LB, and some of
them had Borrelia antibodies in serum (4/24). The control
group reported no symptoms or previous treatment for LB
and had no Borrelia antibodies in serum (Table 1). The
control group and children with previous clinical LB were
matched for gender and geographic location with Borrelia
exposed asymptomatic children (Table 1). All 64 children
were included for analysis with the ELISPOT assay but
some later had to be excluded (n = 16) due to low
responses in postive controls (see Data Handling). These
excluded children did not diﬀer statistically concerning
gender (female 7/16 versus 22/48) or geographic location
(rural living 7/16 versus 19/48) compared to included
children (n = 48). Samples from 41 children were used
for analysis with Luminex due to insuﬃciencies in cell
samples (see Data Handling). The excluded children (n =
23) did not diﬀer statistically concerning gender (female
10/23 versus 19/41) or geograﬁc location (rural living
10/23 versus 16/41) compared to included children (n =
41). Informed consent has been given by all participating
families, and the study was approved by the Regional Ethical
Committee at the Faculty of Health Sciences, Link¨ oping,
Sweden (Dnr 03-547). All laboratory work in this study
(i.e., not the collection and cryopreservation of cells) has
been carried out by one person (S. Hellberg, one of the
authors).
2.1.ELISAAntibodyTestforB.burgdorferis.l. Acommercial
enzyme-linked immunoassay (ELISA) kit, based on the
Borrelia-speciﬁc protein Flagellin, was used (IDEA Borrelia
burgdorferi IgG kit, DakoCytomation, Glostrup, DenmarkClinical and Developmental Immunology 3
Table 1: Subject characteristics at 5 years of age.
Exposed asymptomatic Previous clinical LB Controls
(n = 20) (n = 24) (n = 20)
Gender (f/m) 9/11 11/13 9/11
R u r a l l i v i n g 71 18
Known tick bites 20 24 0
Previous clinical LB
E M 02 20
NB, facial nerve palsy 0 5 0
NB, meningitis 0 1 0
Antibiotic treatment for LB 0 24 0
Borrelia IgG antibodies in serum∗ 20 4 0
Note. The data referred to in the table is given as numbers of children. Some of the children with previous clinical LB presented with several symptoms.
n: number; f: female; m: male; LB: Lyme borreliosis; EM: Erythema migrans; NB: Neuroborreliosis; IgG: immunoglobulin G
∗Based on an ELISA (DAKO) kit for IgG antibodies for Borrelia-speciﬁc ﬂagella antigen [24].
and Oxoid Limited, Hampshire, United Kingdom) [24], and
cut-oﬀforODvalueswassetaccordingtothemanufacturer’s
instructions.
2.2. Isolation, Cryopreservation, and Thawing of Peripheral
Blood Mononuclear Cells (PBMCs). Blood samples were col-
lectedfromtheprimaryhealthcenters,senttotheDivisionof
Pediatrics, Link¨ oping University, and prepared for isolation
and cryopreservation as described in earlier studies [25].
When the time came for analyses, the samples were taken
out of the nitrogen container and thawed in a 37◦Cw a t e r
bath. Once thawed, the cell suspension was immediately
transferredintoa15mLpolypropylenetube,andprewarmed
(37◦C) tissue culture media (TCM) containing 10% heat-
inactivated fetal calf serum (FCS; Sigma Aldrich, Stockholm,
Sweden) and Iscove’s modiﬁcation of Dulbecco’s medium
(GIBCO, Paisley, UK) supplemented with L-glutamine
(SigmaAldrichSwedenAB,Stockholm,Sweden)292mgL−1,
MEM (minimum essential media) 100 X nonessential
amino acids 10μgmL −1 (Invitrogen AB, Paisley, UK), peni-
cillin 50IUmL−1,s t r e p t o m y c i n5 0 μgmL −1 (BioWhittaker
Europe, Essen, Germany), and NaHCO33.024gL−1 (Merck
KGaA, Damstedt, Germany) were added dropwise along the
wall of the tube to avoid osmotic shock in the cells. The
cell suspension was centrifuged for 10 minutes at 400 ×ga t
room temperature and the supernatant discarded. The cells
were washed twice in TCM at 400 ×g at RT for 10min.
The cells were counted using a B¨ urker chamber in a phase-
contrast microscope (Carl Zeiss AB, Stockholm, Sweden).
The cell membrane integrity, that is, viability of the cells, was
assessed with trypan blue exclusion and ranged from 83% to
99% with a median of 95%. The concentration of cells was
adjusted to 1 × 106 PBMCmL−1.
2.3.PreparationoftheBorreliaOuterSurfaceProtein-Enriched
Fraction (OF) Antigen. The cells, both in ELISPOT assay
and in vitro stimulation for Luminex assay, were stimulated
by OF, consisting primarily of OspA and OspB from B.
garinii strain Ip90. This antigen was chosen because it has
previously been shown to be eﬀective in diﬀerentiating
between individuals with Borrelia infections and controls
in ELISPOT assay for speciﬁc Borrelia IFN-γ and IL-4
secretion [17, 23]. The antigen was prepared as described
in earlier reports [26, 27], and the optimal concentration of
the Borrelia OF antigen was determined through testing of
diﬀerent antigen concentrations (54, 18, 6, and 2μgm L −1)
on an adult patient sample with conﬁrmed neuroborreliosis
(NB) by ELISPOT analysis. The ﬁnal optimal concentration
of Borrelia OF antigen was therefore 6μg/mL−1 in the
ELISPOT assay. In the Luminex assay, a concentration of
12μg/mL was used.
2.4. ELISPOT Analysis for IFN-γ, IL-4, and IL-17. To deter-
mine the T-cell response to B. burgdorferi s.l., an ELISPOT
assay was used to assess the number of Borrelia-speciﬁc IFN-
γ-, IL-4- and IL-17-secreting cells. The ELISPOT analyses,
originally described by Czerkinsky et al. [28], were per-
formed according to the instructions provided by the man-
ufacturer (Mabtech AB, Nacka, Sweden) and as described
in detail in earlier studies [17, 23]. Tetanus toxoid (TT;
Swedish Institute for Infectious Disease Control, Stockholm,
Sweden) and phytohemagglutinin A (PHA; Sigma-Aldrich
AB, Stockholm, Sweden) were used as positive controls,
representing recall antigen and polyclonal stimulation,
respectively, at a ﬁnal concentration of 5 LF units mL−1
for TT and 20μgmL −1 for PHA. A peptide pool consisting
of 32 peptides derived from the human Cytomegalovirus,
Epstein-Barr virus, and Inﬂuenza virus (CEF; Mabtech
AB, Nacka, Sweden) was also included as an additional
positive control for IFN-γ responses and used at a ﬁnal
concentration of 2μgmL −1. As for negative controls, wells
with TCM were used without cells. All samples (except
wells containing only PHA or cell medium alone) were
assayed in triplicate although some samples could only
be assayed in duplicate due to low cell count. The spots
were counted manually by dissection microscope and by
semiautomatic AID EliSpot Reader system/HR version 3.2.3
(AIDautoimmunediagnosticsGmbH,Strassberg,Germany)
in a blinded manner on one single occasion by the same4 Clinical and Developmental Immunology
person (S. Hellberg, one of the authors). Each spot counted
represented one cytokine-producing cell.
2.5. Luminex Analysis for IL-1β, IL-6, IL-10, IL-12(p70), and
TNF. Half a million PMBCs diluted in 0.5mL TCM supple-
mented with 10% FCS (Sigma Aldrich, Stockholm, Sweden)
were cultured together with OF from B. garinii and LPS
(Sigma-Aldrich AB, Stockholm, Sweden) from Salmonella
typhimurium at ﬁnal concentrations of 12μgm L −1,1 n g
mL−1, and 100ng mL−1, respectively, or without antigen,
at 37◦C, 5% CO2, for 24 hours. After 24 hours, the cells
were centrifuged (400 ×g at RT), and the supernatants were
collected and frozen at −70◦C until used for the Luminex
analysis of cytokines in the samples. The levels of cytokines
IL-1β, IL-6, IL-10, IL-12(p70), and TNF were measured in
the PBMC supernatants by a Bio-Plex Pro Human Cytokine
Panel Kit (Bio-Rad Laboratories, Calif, USA). All assays were
carried out in accordance with the instructions provided
by the manufacturer. The plates were then analyzed using
Luminex200 (Invitrogen, Merelbeke, Belgium). The analysis
conditionwassettoaminimumof100beadsperregion.The
raw data, median ﬂuorescent intensity (MFI), was analyzed
using xPONENT 3.1 (Luminex Corporation, Austin, Tex,
USA). The quantiﬁable ranges for the standard curves were
for IL-1β 1.91–1959.31pgmL−1, IL-6 1.54–25171pg mL−1,
IL-10 1.48–6076pgmL−1, TNF 4.75–19438.75pgmL−1,a n d
for IL-12(p70) 2.19–8988pgmL−1. Values below the lowest
detection limit of the standard curve were assigned half
the value of the detection limit, and values above highest
detection limit were assigned double the value of the
detection limit.
2.6. Data Handling. Regarding the ELISPOT assay, the me-
dian of the triplicates or duplicates was used for the analysis
of cytokine-secreting cells. The method for determining
Borrelia-speciﬁc secretion in this study has previously been
implemented in other studies [18–20] and is based on both
the unstimulated, spontaneous secretion and the antigen-
stimulated secretion of the cells. The Borrelia-speciﬁc secre-
tion was determined by subtracting the number of spots
from the wells with cell suspension and medium (i.e.,
the spontaneous secretion) from the number of spots in
the OF-antigen-stimulated wells (i.e., Borrelia-stimulated
secretion) [20]. Both the Borrelia-speciﬁc secretion and the
spontaneous secretion are interesting to show to give a
full picture of immune responses, and both are therefore
reported in Results, Discussion, and Figures.
All 64 samples were investigated by the ELISPOT assay.
However, as there were low responses in some of the positive
controls, deﬁned criteria were used to assure that cells had
the ability to respond. These criteria were mainly based
on the PHA responses for IFN-γ. Samples with a high
PHA response for IFN-γ (over 300 spots) were all included
(n = 27). Samples with PHA response of 200–300 spots
were included if they also had an apparent antigen-induced
response for TT and CEF (for more than one cytokine) or
a strong PHA response for both IL-4 and IL-17 (n = 19).
Based on previous experience, samples with a PHA response
forIFN-γshowinglessthan200spotswereexcluded(n = 16)
with the exception of two samples showing strong antigen-
induced responses for both TT and CEF (for more than two
cytokines) and strong PHA responses for both IL-4 and IL-
17 (n = 2). All these considerations were blinded from the
belonging to groups and the Borrelia-stimulated secretion.
With regard to the Luminex assay, 41 samples were
available and all were analyzed. The ability of the cells to
respond to stimuli was assessed by the ratio between the
samples stimulated with LPS and the spontaneous secretion.
Samples were included if they had an LPS/spontaneous
secretion ratio of ﬁve or more for any of the analyzed
cytokines. Based on these criteria, all samples were valid and
couldbeincluded foranalysis(n = 41).TheBorreliainduced
secretion was obtained by subtracting spontaneous secretion
from the samples stimulated with Borrelia OF antigen as
previously implemented for the ELISPOT assay.
2.7. Statistical Analysis. Statistical Products and Service
Solutions (SPSS), version 17.0 for Windows was used for
the statistical analysis. The Kruskal-Wallis test was used as
a pretest for comparison of the immunological parameters
betweenthegroups.Mann-WhitneyU testwasusedasapost
hoc test when the P value for Kruskal-Wallis test was P<
0.08. For Mann-Whitney, a level of P<0.05 was considered
statistically signiﬁcant. Since the cytokines analyzed in this
study were viewed as part of a pattern and not as separate
events, no corrections for multiple comparisons were made.
3. Results
3.1. Number of IFN-γ-, IL-4- and IL-17- Secreting Cells
MeasuredbyELISPOT. Allgroupsdisplayedapredominance
of Borrelia-speciﬁc IFN-γ-secreting cells as compared to IL-
4- and IL-17-secreting cells. However, no signiﬁcant diﬀer-
ences were found between Borrelia exposed asymptomatic
children and children with previous clinical LB regarding
the number of Borrelia-speciﬁc IFN-γ-, IL-4-, and IL-17-
secreting cells (Figure 1). Moreover, no signiﬁcant diﬀerence
could be found in comparison to the control group for any
of the analyzed cytokines. Some of the individuals in all three
groupshadnegativevaluesfortheBorrelia-speciﬁcsecretion,
that is, the spontaneous secretion was higher than the OF-
stimulated secretion (Figure 1).
When analyzing the number of spontaneous secreting
cells, indicating the nonstimulated background activity of
cytokine secretion, no signiﬁcant diﬀerences in IFN-γ,I L -
4, or IL-17 was found between any of the groups (Figure 2).
A ratio between the numbers of IL-4- and IFN-γ-s p o n t a -
neously secreting cells, assessing the Th2/Th1 balance, did
not show any signiﬁcant diﬀerences across groups (data
not shown). PHA-induced secretion, indicating the ability
of the cells to respond to mitogenic stimulation, elicited a
stronger response for IFN-γ than for IL-4 and IL-17, but no
diﬀerences were found between groups (data not shown).
3.2. IL-1β, IL-6, IL-10, IL-12(p70), and TNF Secretion
Measured by Luminex. The Borrelia induced secretion of
IL-1β, IL-6, IL-10, and TNF were readily detectable with theClinical and Developmental Immunology 5
Table 2: The OF induced cytokine secretion in PBMCs by Luminex.
Cytokine Exposed asymptomatic Previous clinical LB Controls
IL-1β 309 (183–846) 341 (132–1223) 340 (162–800)
IL-6 6805 (3528–12749) 7304 (3281–50303) 7335 (2578–12324)
IL-10 130 (38–442) 129 (42–572) 123 (37–684)
IL-12(p70) 1 (0-1) 1 (0-1) 1 (0-1)
TNF 676 (241–2311) 561 (209–1724) 628 (226–1373)
NOTE. The data referred to in the table is given as median values in pg/mL (range in parenthesis).
OF: outer surface protein enriched fraction; PBMCs: peripheral blood mononuclear cells; LB: Lyme Borreliosis; IL = interleukin; TNF: tumour necrosis factor.
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Figure 1: The number of Borrelia-speciﬁc IFN-γ-secreting cells
(opencircle), IL-4-secreting cells (opensquare)and IL-17-secreting
cells (open triangle), per 100 000 PBMCs as measured by ELISPOT
in diﬀerent groups. The ﬁlled circles, squares, and triangles
represent children in the previous clinical LB group with Borre-
lia seropositivity. The Borrelia-speciﬁc secretions are net values
obtained after subtracting the number of spontaneous cytokine-
secreting cells from the number of outer surface protein fraction
(OF-) antigen-speciﬁc cytokine-secreting cells. The median values
arenotedaslinesintheﬁgure.Nostatisticallysigniﬁcantdiﬀerences
were found between groups.
Luminex assay, whereas the Borrelia induced secretion of IL-
12(p70) was undetectable in all samples (Table 2). Moreover,
the IL-12(p70) levels were also below the detection limit
also in 32 of the 40 samples stimulated with LPS and did
not exceeded 8pg/mL in the remaining 8 samples. Thus,
levels of IL-12(p70) were not considered interpretable. Of
the remaining cytokines, IL-6 was present in the overall
highest concentration in all groups and IL-10 in the lowest
concentration in all groups (Table 2).
As for the Borrelia induced secretion, no signiﬁcant dif-
ferences were found between Borrelia exposed asymptomatic
children, children with previous clinical LB, and controls
with regard to IL-1β, IL-6, IL-10, and TNF (Figure 3). The
spontaneous secretion did not diﬀer signiﬁcantly between
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Figure 2: The number of spontaneously IFN-γ-secreting cells
(open circle), IL-4-secreting cells (open square), and IL-17-
secreting cells (open triangle) per 100 000 PBMCs as measured
by ELISPOT in diﬀerent groups. The ﬁlled circles, squares, and
triangles represent the children in the previous clinical LB group
with Borrelia seropositivity. The median values are noted as lines
in the ﬁgure. No statistically signiﬁcant diﬀerences were found
between groups.
groupsforanyofthecytokinesalthoughtherewasatendency
(P = 0.057) towards an increased spontaneous secretion
of IL-6 in children with previous clinical LB as compared
to Borrelia exposed asymptomatic children (Figure 4). The
ratio between LPS-stimulated secretion and the spontaneous
secretion, indicating the ability of the cells to respond to
a TLR4-agonistic stimulus, was (median values with range
in parenthesis): 301(9–2051) for IL-1β; 314(8–4262) for IL-
6; 134(17–450) for IL-10 and 66(7–652) for TNF (data not
shown).
4. Discussion
Inthisstudy,wehaveinvestigatedtheBorrelia-speciﬁc(adap-
tive) and the Borrelia induced (innate) immune responses in
Borrelia exposed asymptomatic children and children with6 Clinical and Developmental Immunology
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Figure 3: The Borrelia-induced secretion of IL-1β, IL-6, IL-10, and TNF in PBMC supernatants from Borrelia exposed asymptomatic
children (ﬁlled circle), children with previous clinical LB (open square), and controls (ﬁlled triangle) as measured by Luminex. The Borrelia
induced secretions are net values obtained after subtracting the level of spontaneous cytokine secretion from the level of outer surface
protein-fraction(OF-)stimulatedcytokinesecretion.Themedianvaluesarenotedaslinesintheﬁgure.Nostatisticallysigniﬁcantdiﬀerences
were found between groups.
previous clinical LB. Our aim was to better understand
immunological mechanisms that could explain why some
individuals develop clinical manifestations of LB and others
do not. Interestingly, we found no diﬀerences in the number
of Borrelia-speciﬁc IFN-γ-, IL-4-, and IL-17-secreting cells
when comparing Borrelia exposed asymptomatic children,
children with previous clinical LB, and controls. This lack of
Borrelia-speciﬁc (adaptive) immune responsiveness is con-
gruentwithearlierstudiesonBorreliaexposedasymptomatic
adultswherenodiﬀerencesinthenumberofBorrelia-speciﬁc
IFN-γ- and IL-4-secreting cells were found compared to
patients with clinical LB [20]. Our negative ﬁndings are
further supported by Jarefors et al. [29], who found no
diﬀerences in IFN-γ secretion between asymptomatic adults
and patients with previous clinical LB [29]. As for the
innate immune responses, no signiﬁcant diﬀerences in
the Borrelia induced cytokine IL-1β, IL-6, IL-10, or TNF
secretion between groups were found in our study, whereas
in a previous study by Sj¨ owall et al. [21], an increased
number of Borrelia-induced TNF-secreting DCs were found
in asymptomatic adults as compared to patients with a
history of NB [21].
We are well aware of the fact that the number of patients
in each group is rather low; but with well-characterized
patient groups, a proper design of the study and nonpara-
metric statistic calculations, the results should be reliable.
Furthermore, the fact that the number of Borrelia-speciﬁc
IFN-γ- and IL-4-secreting cells was generally lower as
compared to earlier studies [17, 18, 20] led us to consider
that the responsiveness of the cells to stimuli might have
been reduced due to the quality of the cells after freezing
(previous studies were performed on freshly isolated cells).Clinical and Developmental Immunology 7
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Figure 4: The spontaneous secretion of IL-1β, IL-6, IL-10, and TNF in PBMC supernatants from Borrelia exposed asymptomatic children
(ﬁlled circle), children with previous clinical LB (open square), and controls (ﬁlled triangle) as measured by Luminex. The median values
are noted as lines in the ﬁgure. There was a tendency to higher IL-6 in children with previous clinical LB compared to Borrelia exposed
asymptomatic children, otherwise no statistically signiﬁcant diﬀerences were found between groups.
However, the response to PHA was similar to that obtained
from another study on LB in adults [17], and additionally
the response to LPS was substantially higher than the
spontaneous secretion which, considered together, conﬁrms
the ability of the cells to respond to stimuli. The use of
cryopreserved PBMCs in this study was necessary due to
the design of the study, as it would have been impossible
to test cellular immune responses in freshly isolated PBMCs
from thousands of unselected children. Earlier reports on
cryopreservation eﬀects on cytokine secretion by ELISPOT
showed a general decrease in the IL-4 secretion in cryopre-
served cells as compared to fresh cells both in spontaneous
and allergen-induced secretion, whereas IFN-γ secretion was
less aﬀected [30]. Thus, to some extent, the cryopreservation
could explain the low levels of IL-4-secreting cells found
in this study as compared to earlier studies with freshly
prepared PBMCs from children (1–17 years old) [18]. It is
alsoimportanttonotethatbloodsamplesfromchildrenwere
taken postinfection and not during the actual infection, in
accordance with the design of the study.
The young age of the children has also to be taken into
consideration. The ability to respond with IFN-γ is impaired
inneonates[31]anddevelopsduringchildhood[32,33].The
children in our study were all 5 years of age, and thus one
would expect full capacity to respond with IFN-γ to stimuli
[34, 35]. A similar capacity was found when comparing the
PHA-induced IFN-γ secretion in our present study to the
PHA-induced IFN-γ secretion in adults [17].
Whether or not children with previous clinical LB are
“truly” Borrelia exposed, patients may be a matter for
discussion. Data in our present study is based on self-
reported information that may have weaknesses. However,
most patients did report a previous EM, which is a clear
clinical diagnosis, and although self-reported, the diagnosis8 Clinical and Developmental Immunology
was stated to be set by a physician and treated with
antibiotics. Very few of the children with previous clinical
LB were Borrelia seropositive (n = 4, Table 1), but this was
expected since EM is a clinical diagnosis set by a physician,
the sensitivity of the test in EM is low and antibody levels
may be reduced after antibiotic treatment [36]. Previous
antibiotic treatment in this group could theoretically also
have inﬂuenced immune responses. Moreover, one must
remember that our study mainly evaluates children with
previous EM (only 5 children with facial palsy and 1 with
meningitis), thus conclusions on immune responses in
disseminated LB could not be drawn from our data.
Furthermore, whether or not Borrelia exposed asymp-
tomatic children are “truly” Borrelia exposed or falsely
seropositive may also be a matter for discussion. We have
not carried out any conﬁrmatory test since the speciﬁcity of
the test is high [37], and in earlier studies, a Borrelia-speciﬁc
T-cell response in PBMCs was noted in Borrelia exposed
asymptomatic adults, certifying a true exposure [38]. Thus,
we believe that false seropositive specimens should not be a
problem in our material.
We found a tendency towards higher levels of spon-
taneous secretion of IL-6 (by Luminex) in children with
previous clinical LB (Figure 4). IL-6 is a pleiotropic cytokine
thatmainly mediatesproinﬂammatoryeﬀects,and itinduces
secretion of IL-17 from na¨ ıve T cells [39] and may therefore,
together with IL-17, be involved in pathogenesis of LB.
R e c e n t l y ,i tw a ss u g g e s t e dt h a tI L - 1 7m i g h tc o n t r i b u t et o
the pathogenesis in Lyme arthritis and in NB [40, 41].
Thus, one could speculate that IL-6 together with IL-17 may
be involved in inﬂammatory mechanisms contributing to
clinical manifestations of LB. However, in the present study,
we found only a tendency of elevated spontaneous secretion
of IL-6 but no Borrelia induced IL-6 or IL-17 secretion. This
could possibly be explained by the fact that we have analyzed
PBMCs after inﬂammation and not specimen from immune
privileged sites during active inﬂammation. Thus, the role of
IL-6 together with IL-17 is certainly interesting regarding the
pathogenesis in LB but needs further investigation.
Finally, why some individuals develop a clinical disease
upon encountering B. burgdorferi s.l. and some do not
remains unclear. Whether or not speciﬁc properties of
the host’s immune system are of importance is still not
understood,and,admittedly,theremightbeotherimportant
aspects. For example, the Borrelia genospecies infecting
the human might play a substantial role in the diﬀerent
clinical outcomes observed in LB. It is well established that
the diﬀerent genospecies of B. burgdorferi s.l. can cause
diﬀerent clinical manifestations, and it is also well known
that diﬀerent genospecies have diﬀerent abilities in escaping
the complement system, thereby avoiding elimination [42].
Theseaspects,aswellastheindividualgeneticpredisposition
might be crucial factors in understanding mechanisms in the
spirochete-host interaction, and future studies are warranted
in these ﬁelds.
Inconclusion,ourresultsshownodiﬀerencesinadaptive
or innate immune responsiveness to B. burgdorferi s.l. when
comparing Borrelia exposed asymptomatic children and
children with previous clinical LB. Thus, immunological
mechanisms of importance for eradicating the spirochete
eﬀectively without developing clinical manifestations of LB
remain unknown.
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